Connor, Clark & Lunn Investment Management (CC&L)
RXRX icon

Connor, Clark & Lunn Investment Management (CC&L)’s Recursion Pharmaceuticals RXRX Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-227,892
Closed -$1.52M – 1470
2023
Q1 		$1.52M Buy
227,892
+83,879
+58% +$665K 0.01% 622
2022
Q4 		$1.11M Buy
+144,013
New +$1.41M 0.01% 678

Other funds holding RXRX

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
DCI
Data Collective IV Palo Alto, California $55.9M AUM 49.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s RXRX Position: Q2 2023 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Recursion Pharmaceuticals (RXRX) in Q2 2023, closing a stake of 227,892 shares — an estimated $1.52M sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in RXRX in Q4 2022 and held it in 2 quarters. The position peaked at $1.52M in Q1 2023. 158 funds tracked by Wall St. Rank hold RXRX as of Q2 2023.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Recursion Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 227,892 Recursion Pharmaceuticals shares in Q2 2023, an estimated $1.52M.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Recursion Pharmaceuticals in Q4 2022 and held it in 2 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Recursion Pharmaceuticals position peaked at $1.52M in Q1 2023.
  • 158 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2023.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2023, filed 10 Aug 2023.